Brokerages expect Curis, Inc. (NASDAQ:CRIS) to report sales of $2.17 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Curis’ earnings. The lowest sales estimate is $2.03 million and the highest is $2.30 million. Curis posted sales of $1.76 million during the same quarter last year, which would indicate a positive year over year growth rate of 23.3%. The business is scheduled to issue its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Curis will report full-year sales of $2.17 million for the current financial year, with estimates ranging from $8.26 million to $8.50 million. For the next year, analysts anticipate that the firm will report sales of $9.47 million per share, with estimates ranging from $8.54 million to $10.40 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Curis.
Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm had revenue of $2.10 million during the quarter, compared to analyst estimates of $2.08 million. During the same period in the previous year, the company posted ($0.09) EPS. Curis’s revenue for the quarter was up 23.5% compared to the same quarter last year.
A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $6.00.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRIS. Point72 Asset Management L.P. purchased a new position in shares of Curis during the 1st quarter valued at $1,391,000. Perceptive Advisors LLC purchased a new position in shares of Curis during the 1st quarter valued at $1,390,000. FMR LLC grew its position in shares of Curis by 2.7% during the 1st quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock valued at $42,067,000 after purchasing an additional 393,582 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Curis by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock valued at $13,421,000 after purchasing an additional 304,268 shares in the last quarter. Finally, State Street Corp grew its position in shares of Curis by 10.4% during the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after purchasing an additional 175,424 shares in the last quarter. Hedge funds and other institutional investors own 44.72% of the company’s stock.
Curis (NASDAQ:CRIS) traded down 3.03% during trading on Tuesday, hitting $1.60. The stock had a trading volume of 852,569 shares. The firm has a 50 day moving average price of $1.76 and a 200-day moving average price of $1.98. The firm’s market capitalization is $230.20 million. Curis has a 1-year low of $1.47 and a 1-year high of $3.72.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.